AI Company Narrativa Teams Up with the Leukemia and Lymphoma Society to Improve Regulatory Documentation Process
The two groups will implement AI technology with an already existing precision medicine trial model.
Announced at SCOPE 2023, Los Angeles based AI company Narrativa is partnering with the Leukemia and Lymphoma Society to improve regulatory documentation. In order to achieve, the tech company is applying artificial intelligence models and automated data analysis to enhance the Beat AML Master Clinical Trial.
The trial is the first precision medicine clinical trial for blood cancer. As is the case with most precision medicine models, the trial uses advanced genomic technology to determine the best targeted treatment for each patient. The trial launched in 2016.
In a press release sent to ACT, Narrativa’s technology will automate the production of patient narratives and clinical study reports, along with other elements of the regulatory process. This should speed up the process and reduce the time it takes for new treatments to get approved and released to market.
Jenifer Bittinger, president of Narrativa, said, “The Life Sciences industry is at a precipice. Utilizing the advancements of artificial intelligence to automate clinical trial regulatory documentation will bring drugs to market faster and ultimately save more lives. Our goal is to use AI to improve systems within enterprises, but to also use it for good. We want to improve humanity.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
